title: Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies.
abstract: Our increased understanding of ovarian cancer's blueprints (mediated by DNA and RNA) and behavior (mediated by proteins) points to wide differences across patients that cannot be depicted by histology alone. Conventional diagnosis usually entails an adequate tissue biopsy, which limits serial testing. There is thus a motivation to shift towards easier to obtain clinical samples (e.g., ascites or blood). In response, investigators are increasingly leveraging alternative circulating biomarkers in blood or proximal fluids and harnessing novel profiling platforms to help explore treatment-related effects on such biomarkers in serial fashion. In this review, we discuss how new nanotechnologies we developed intersect with alternative ovarian cancer biomarkers for improved understanding of metastases and therapeutic response.
authors.affiliation: Massachusetts General Hospital Cancer Center, 55 Fruit St, Yawkey 9E, Boston, MA, 02114, USA, Castro.Cesar@mgh.harvard.edu.
authors.forename: Cesar M
authors.initials: CM
authors.lastname: Castro
authors.forename: Hyungsoon
authors.initials: H
authors.lastname: Im
authors.forename: Christine
authors.initials: C
authors.lastname: Le
authors.forename: Hakho
authors.initials: H
authors.lastname: Lee
authors.forename: Ralph
authors.initials: R
authors.lastname: Weissleder
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Birrer
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D005260:Female; D006801:Humans; D009682:Magnetic Resonance Spectroscopy / Q000295:instrumentation / Q000379:methods*; D036103:Nanotechnology / Q000295:instrumentation / Q000379:methods*; D009360:Neoplastic Cells, Circulating / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D014408:Biomarkers, Tumor